Are you a healthcare professional?

This website contains promotional information for Chiesi's respiratory products, and is intended solely for UK healthcare professionals. Please confirm below, or go back to the home page.

UK-RES-2000248 Feb 2020

You are now leaving Chiesi's website

By clicking this link, you will be taken to a website that is not owned or controlled by Chiesi. Chiesi is not responsible for the content provided on that site.

Go back

UK-RES-2000003 Jan 2020

Trimbow® Logo - beclometasone/formoterol/glycopyrronium (87/5/9 mcg) Extrafine formulation

Think triple (ICS/LABA/LAMA),
think Trimbow

The only extrafine formulation ICS/LABA/LAMA combination1,2

Designed to reach the large and small airways1,3

Trimbow pMDI 87/5/9 is indicated for maintenance treatment in adult patients with moderate to severe COPD who are not adequately treated by a combination of an inhaled corticosteroid and a long-acting β2-agonist or a combination of a long-acting β2-agonist and a long-acting muscarinic antagonist (for effects on symptoms control and prevention of exacerbations see section 5.1 of the Trimbow SPC).1

Trimbow® Device

Each dose contains three molecules: 1

  • Beclometasone
  • Formoterol
  • Glycopyrronium

Trimbow is for your adult patients with moderate to severe COPD not adequately treated with ICS/LABA or LABA/LAMA who need triple therapy1

Extrafine formulation like Fostair® (beclometasone/formoterol)1,4

Familiar pMDI device, b.d. dosing and licensed for use with an AeroChamber Plus® spacer1,5,6

Reduction in exacerbations vs.:1,7-9

  • LAMA (Spiriva HandiHaler)
  • ICS/LABA (Fostair pMDI 100/6) – secondary endpoint
  • LABA/LAMA (Ultibro Breezhaler)

Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store. Adverse events should also be reported to Chiesi Limited on 0800 0092329 (UK) or PV.UK@Chiesi.com.